Barr to Challenge Patents Protecting Prefest Hormone Therapy
Each Prefest tablet contains 1 mg estradiol alone or 1 mg estradiol and 0.09 mg norgestimate, and is indicated in women with an intact uterus for the treatment of moderate to severe menopausal symptoms.
Barr filed an Abbreviated New Drug Application for Prefest with the Food and Drug Administration in August 2003, and received notification of the application's acceptance in September 2003. Barr notified King and Jencap Research, Ltd.,...
To view the full article, register now.